



INTERNATIONAL JOURNAL OF PHARMACY AND ANALYTICAL RESEARCH

ISSN: 2320-2831

IJPAP | Vol.9 | Issue 3 | Jul - Sep - 2020

Journal Home page: www.ijpar.com

Research Study

Open Access

Method development and the Simultaneous estimation of Escitalopram and L-methylfolate in tablet dosage form by RP-HPLC Method

Dr G Subba Rao and Mudavath Anjamma

St. Xavier Institute of Pharmacy, Deenapur, Phirangipuram, Guntur, India

*Corresponding Author: Dr G Subba Rao

Email: preddy1504@gmail.com

ABSTRACT

Analytical Chemistry seeks ever-improved means of measuring the chemical composition of natural and artificial materials. The techniques of this science are used to identify the substances, which may be present in a material, and to determine the exact amounts of the identified substances. Analytical chemists work to improve the reliability of existing techniques to meet the demands for better chemical measurements, which arise constantly in our society. They adapt proven methodologies to new kinds of materials or to answer new questions about their composition. Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. L-methylfolate is the only metabolite of folate that can cross the blood-brain barrier, and it is this form that can directly impact several important CNS reactions, most notably the synthesis of three important neurotransmitters: serotonin, norepinephrine, and dopamine. Simultaneous estimation of Escitalopram and L-methylfolate in tablet dosage form by RP-HPLC Method. The method was validated as for ICH guidelines and it can be used for the routine analysis of Escitalopram and L-methylfolate in tablet dosage form.

Keywords: Escitalopram, methylfolate, estimation, RP-HPLC, method development

INTRODUCTION

Pharmaceutical analysis is a branch of practical chemistry that involves a series of process for identification, determination, quantification and purification of a substance, separation of the components of a solution or mixture, or determination of structure of chemical compounds (1). The substance may be a single compound or a mixture of compounds and it may be in any of the dosage form. The substance used as pharmaceuticals are animals, plants, microorganisms, minerals and various synthetic products (2).

Analytical Chemistry seeks ever-improved means of measuring the chemical composition of natural and artificial materials. The techniques of this science are used to identify the substances, which may be present in a material, and to determine the exact amounts of the identified substances. Analytical chemists work to improve the reliability of

existing techniques to meet the demands for better chemical measurements, which arise constantly in our society. They adapt proven methodologies to new kinds of materials or to answer new questions about their composition (3). They carry out research to discover completely new principles of measurement and are at the forefront of the utilization of major discoveries such as lasers and microchip devices for practical purposes. They make important contributions to many other fields as diverse as forensic chemistry, archaeology, and space science (4). Analytical Techniques used are as follows (5):

Spectrometric techniques

- Ultraviolet and visible spectrophotometry
- Fluorescence and phosphorescence spectrophotometry
- Atomic Spectrometry (emission and absorption)
- Infrared Spectrophotometry
- Raman Spectroscopy

- X-Ray Spectroscopy
- Radiochemical Techniques including activation analysis
- Nuclear Magnetic Resonance Spectroscopy
- Electron Spin Resonance Spectroscopy

Electrochemical techniques

- Potentiometry
- Voltametry
- Voltametric Techniques
- Stripping Techniques
- Amperometric Techniques
- Colorimetry
- Electrogravimetry
- Conductance Techniques

Chromatographic techniques

- Gas Chromatography
- High Performance Liquid Chromatography
- High Performance Thin Layer Chromatography

Miscellaneous techniques

- Thermal Analysis (DTA, DTG)
- Mass Spectrometry
- Kinetic Techniques

Hyphenated techniques

- GC-MS (Gas Chromatography – Mass Spectrometry)
- ICP-MS (Inductively Coupled Plasma - Mass Spectrometry)
- GC-IR (Gas Chromatography – Infrared Spectroscopy)
- MS-MS (Mass Spectrometry – Mass Spectrometry)

Methods In Chromatography

According to nature of stationary and mobile phase

- Solid liquid chromatography
- Liquid-liquid chromatography
- Gas Solid chromatography
- Gas liquid chromatography

According to principle of separation

A. Adsorption chromatography

- Gas Solid chromatography
- Thin layer chromatography
- Column chromatography
- High performance liquid chromatography
- Affinity phase chromatography
- Hydrophobic Interaction chromatography (HIC)

B. Partition chromatography

- Gas liquid chromatography
- Paper partition chromatography
- Column partition chromatography

Based on modes of chromatography

- Normal phase chromatography
- Reversed phase chromatography

Other types of chromatography

- Size exclusion chromatography (SEC)
- Gel permeation chromatography
- Gel chromatography
- Gel Filtration
- Gel permeation chromatography
- Ion exchange chromatography
- Chiral chromatography

Instrumentation of High Performance Liquid Chromatography

The features of modern HPLC are illustrated in the block diagram compromise of components (6)

1. Pumping system
2. Injector
3. Chromatographic column
4. Detector
5. Data collection device (computer, integrator, or recorder)




Fig 1: Schematic Diagram of HPL

Pumping system

HPLC pumping systems are required to deliver metered amounts of mobile phase at a constant flow rate. Pumping systems that deliver solvent from one or more reservoirs are available. Pressure fluctuations should be reduced, e.g. by

passing the pressurized solvent through a pulse damping device. Tubing connections should be capable of withstanding the pressures developed by the pumping systems. Many HPLC pumps are fitted with a facility for “bleeding” the system of entrapped air bubbles (7). Modern computer- or micro processor- controlled pumping systems

are capable of delivering a mobile phase of either constant (isocratic elution) or varying (gradient elution) composition, according to a defined programmed. In the case of gradient elution, solvent mixing can be achieved on either the low or high-pressure side of the pump(s) depending on the flow rate composition of mobile phase, operating pressure of up to 42000 kpa (6000 psi) can be generated during routine analysis

Injector

The sample solution is usually introduced into the flowing mobile phase at or near the head of the column using an injection system based on an injection valve design which can operate at high pressure. Such an injection system has a fixed-loop or a variable column device which can be operated manually or by an auto sampler. Partially filling of tuber may lead to poorer injection volume precision (8).

Chromatographic column

Columns are usually made of polished stainless steel, or between 50 - 300 mm long, have an internal diameter of between 2 to 5 mm. They are commonly filled with a stationary phase with a particle size of 5 -10 μm . columns with internal diameters of less than 2 mm are often reoffered to as micro bore columns (9). Desirable, the temperature of the mobile phase the column should be kept to constant during an analysis. Most separations are performed at an ambient temperature, but columns may be heated to give better efficiency normally, columns should not be heated above 600C because of the potential for stationary phase degradation or changes occurring to the composition of the mobile phase.


Detector

Ultraviolet/visible (UV/vis) absorption spectrometer are the most commonly used detectors for pharmaceutical analysis. In specific cases fluorescence spectrophotometers, differential refracting meters, electro chemical detectors, light scattering detectors, mass spectrometers, or other special detectors may be used. Here an analyte possesses a chromophoric group that absorbs UV/vis radiation. The UV/vis detector is the most appropriate because of its sensitivity stability. Such a detector is not suitable for detecting analytes with very weak chromophores.

Data Collection Devices

Signals from detector may be collected on chart

Escitalopram



recorders or electronic integrators that vary in complexity in their ability to process, store reprocess chromatographic data. The data storage capacity of these devices is usually limited. Modern data stations are computer based have a large storage capacity to collect, process, store data for possible subsequent reprocessing. Analytical reports can be customized to the needs of the analyst (10).


Selectivity in RP-HPLC

Three main variables can be used in RPC to change selectivity (α) for neutral samples like mobile phase composition, column type temperature. Overall sample retention acceptable is ($0.5 < K < 20$).

- Solvent-strength selectivity:** The best sample resolution will occur for a % B value, where both pairs have the same resolution peak spacing can be explored while % B is varied for optimum sample retention ($0.5 < K < 20$).
- Solvent type selectivity:** A change in organic solvent type is often used to change peak spacing improve resolution. The selection of RPC solvents for this purpose is guided by solvent properties that are believed to affect selectivity, acidity, basicity dipolarity. Only a slight increase (2 to 5 %) in the selectivity (α value) for a critical b pair may be necessary to achieve acceptable resolution. Changing solvent type in RPC is usually the most effective procedure to alter selectivity achieve the separation of multicomponent neutral samples.
- Column type selectivity:** A change in column type can produce useful changes in selectivity over all sample retention. Retention is greater (run time longer) on the stronger (C8 phenyl column) vs. the weaker cyano column. A change of the column is usually less useful than a change in mobile phase type hence this should be tried only after the (11) use of solvent strength or solvent type selectiveness has failed. Usually a C8 or C18 column should be tried first followed by a cyano, then by a phenyl column. Column padings bonded with cyclodextrin (CD) are useful in separation of enantiomeric isomers.
- Temperature selectivity:** Values of K decreases at higher temperature for the RPC separation of neutral compounds. This is less effective for non-ionic compounds as a mean of altering selectivity for improved separation. As the temperature is increased, the relative retention of the polar compounds decreases more rapidly than for the non-polar compounds (12).

Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occasion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are

L-Methylfolate (5-MTHF)



L-methylfolate is the only metabolite of folate that can cross the blood-brain barrier, and it is this form that can directly impact several important CNS reactions, most notably the synthesis of three important neurotransmitters: serotonin, norepinephrine, and dopamine. Folic acid, a water-soluble B-complex vitamin, is found in foods such as liver, kidneys, yeast, and leafy, green vegetables (14). Folic acid is used to diagnose folate deficiency and to treat tropical sprue and megaloblastic and macrocytic anemias, hematologic complications resulting from a deficiency in folic acid.

MATERIALS AND METHODS

HPLC instrument used was of WATERS HPLC 2965 SYSTEM with Auto Injector and PDA 2996 Detector. Software used is Empower 2. UV-VIS spectrophotometer PG Instruments T60 with special bandwidth of 2mm and 10mm and matched quartz was used for measuring absorbance for Escitalopram and L-methylfolate solutions.

Standard Preparation (75µg/ml Escitalopram and 100µg/ml L-methylfolate)

Accurately Weighed and transferred 7.5mg & 10mg of Escitalopram and L-methylfolate working Standards into 50ml and 50ml clean dry volumetric flasks separately, add 3/4th volume of diluent, sonicated for 30 minutes and make up to the final volume with diluents. From the above each stock solution, 1 ml was pipetted out into a 10ml Volumetric flask and then make up to the final volume with diluent (15).

Sample Preparation

20 tablets were weighed and calculate the average weight of each tablet then the tablet powder weight equivalent to 7.5mg of Escitalopram and 10mg of L-methylfolate was transferred into a 10ml volumetric flask, 7ml of diluent added and sonicated for 30 min, further the volume made up with diluent and filtered. From the filtered solution 1ml was pipetted out into a 10 ml volumetric flask and made up to 10ml with diluent.

Degradation studies

Oxidation

To 1 ml of stock solution of Escitalopram & L-

presumed to be linked to its inhibition of CNS neuronal uptake of serotonin (13). In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake.

methylfolate, 1 ml of 20% hydrogen peroxide (H₂O₂) was added separately. The solutions were kept for 30 min at 60°C. For HPLC study, the resultant solution of 10µl was injected into the system and the chromatograms were recorded to assess the stability of sample (16).

Acid Degradation Studies

To 1 ml of stock solutions of Escitalopram & L-methylfolate, 1ml of 2N Hydrochloric acid was added and refluxed for 30mins at 60°C. The resultant solution 10 µl solutions were injected into the system and the chromatograms were recorded to assess the stability of sample (17).

Alkali Degradation Studies

To 1 ml of stock solution Escitalopram & L-methylfolate, 1 ml of 2N sodium hydroxide was added and refluxed for 30mins at 60°C. The resultant solution was diluted to obtain 75µg/ml & 100µg/ml solution and 10 µl were injected into the system and the chromatograms were recorded to assess the stability of sample (18).

Dry Heat Degradation Studies

The standard drug solution was placed in oven at 105°C for 6 h to study dry heat degradation. For HPLC study, the resultant solution was diluted to 75µg/ml & 100µg/ml solution and 10µl were injected into the system and the chromatograms were recorded to assess the stability of the sample (19).

Photo Stability studies

The photochemical stability of the drug was also studied by exposing the 750µg/ml & 100µg/ml solution to UV Light by keeping the beaker in UV Chamber for 1day or 200 Watt hours/m² in photo stability chamber. For HPLC study, the resultant solution was diluted to obtain 75µg/ml & 100µg/ml solutions and 10 µl were injected into the system and the chromatograms were recorded to assess the stability of sample.

Neutral Degradation Studies

To 1ml of stock solution was tested under neutral conditions by refluxing the drug in water for 1h at a temperature of 60° and the resultant solution of 10 µl were

injected into the system and the chromatograms were recorded to assess the stability of the sample (20).

Method Development

Many trials were done by changing columns and Mobile phases and were reported below.

Trial: 1

Column Used : Discovery 250 x 4.6 mm, 5 μ .
 Mobile phase : Water: Methanol (50:50A)
 Flow rate : 1ml/min
 Wavelength : 230nm
 Temperature : 25 $^{\circ}$ C
 Injection Volume : 10 μ l




Fig 2: Trial chromatogram 1

Observation: Resolution was low so further trials was continued.

Trial: 2

Column Used : Discovery 250 x 4.6 mm, 5 μ .
 Mobile phase : Buffer: Acetonitrile (45:55A)
 Buffer : 0.1% OPA solution
 Flow rate : 1ml/min
 Wavelength : 230nm
 Temperature : 30 $^{\circ}$ C
 Injection Volume : 10 μ l




Fig 3: Trial chromatogram 2

Observation: Resolution was low so further trials was continued

Trial: 3

Column Used : Discovery 250 x 4.6 mm, 5 μ .
 Mobile phase : buffer: ACN (53:47A)
 Buffer : 0.1% OPA
 Flow rate : 1ml/min
 Wavelength : 230nm
 Temperature : 30 $^{\circ}$ C

Injection Volume : 10µl




Fig 4: Trial chromatogram 3

Observation: base line noise was observed.

Trial: 4

Column Used : Kromasil 150 x 4.6 mm, 5µ.
 Mobile phase : buffer: Acetonitrile (25:75A)
 Buffer : 0.1%OPA solution
 Flow rate : 1ml/min
 Wavelength : 230nm
 Temperature : 30° C
 Injection Volume : 10µl




Fig 5: Trial chromatogram 4

Observation: peak shape and retention time was not good.

Trial: 5

Column Used : Discovery 250 x 4.6 mm, 5µ.
 Buffer : 0.1% OPA solution
 Mobile phase : buffer: Acetonitrile (55:45)
 Flow rate : 1.0ml/min
 Diluent : water: ACN (50:50)
 Wavelength : 230nm
 Temperature : 30° C
 Injection Volume : 10µl




Fig 6: Trial chromatogram 5

Observation: peak shape and retention time is good .

Optimized Method: Drugs were eluted with good retention time, resolution; all the system suitable parameters like Plate count and Tailing factor were within the limits.

Column Used : Discovery 250 x 4.6 mm, 5 μ .
 Buffer : 0.1% OPA solution
 Mobile phase : buffer: Acetonitrile (55:45)
 Flow rate : 1.0ml/min
 Diluent : water:acn: 50:50
 Wavelength : 230nm
 Temperature : 30°C
 Injection Volume : 10 μ l




Fig 7: Optimized chromatogram of Escitalopram and L-methylfolate

Observation: peak shape and retention time is good

RESULTS AND DISCUSSIONS

Method Development

For the method development several trials were carried out and reported. These leads to the optimized chromatographic conditions for the estimation of Escitalopram and L-methylfolate in pharmaceutical dosage form. Initially various mobile phase and stationary phase were tested in an attempt to obtain the best resolution for Escitalopram and L-methylfolate. The mobile phase consisting of water pH adjusted to 2 with Orthophosphoric acid, at a flow rate of 1 ml/min was chosen for method development and validation of Escitalopram and L-methylfolate by RP-HPLC method. The detection was selected at 218nm, using reverse phase Discovery

C18(250mm x 4.6 mm, 5m)column, the retention time of Escitalopram and L-methylfolate were found to be 3.010min and 3.668min respectively. The total run time was 7 minutes.

A mobile phase consisting of water pH adjusted to 2 with Orthophosphoric acid was selected to achieve maximum separation and sensitivity. The flow rate of 1 ml/min gave an optimal signal to noise ratio with reasonable separation time.

Method Validation

System suitability

All the system suitability parameters are within range and satisfactory as per ICH guidelines




Fig 8: System suitability chromatogram

Table 1: System suitability parameters of chromatogram

| Property | Escitalopram | L-methylfolate |
|----------------------------------|--------------|----------------|
| Retention time (t _R) | 3.046min | 3.662min |
| Theoretical plates (N) | 8669 ± 63.48 | 10198 ± 63.48 |
| Tailing factor (T) | 1.07 ± 0.117 | 1.19 ± 0.117 |

Observation

- Retention time for Escitalopram and L-methylfolate 3.046 min and 3.662 min respectively.
- Tailing factor of Escitalopram and L-methylfolate 1.07 ± 0.117 and 1.19 ± 0.117 respectively.
- Number of theoretical plates for Escitalopram and L-methylfolate 8669 ± 63.48 and 10198 ± 63.48 respectively.

Discussion

All the system suitability parameters are found to be satisfactory. The peak is reasonably symmetrical. High numbers of theoretical plates indicate efficient performance of the column with reasonable retention times.

Table 2: Calibration data of Escitalopram and L-methylfolate method.

| S.no | Concentration Escitalopram (µg/ml) | Response | Concentration L-methylfolate (µg/ml) | Response |
|------|---------------------------------------|----------|---|----------|
| 1 | 0 | 0 | 0 | 0 |
| 2 | 18.75 | 272570 | 25 | 381343 |
| 3 | 37.5 | 528238 | 50 | 720007 |
| 4 | 56.25 | 814528 | 75 | 1081548 |
| 5 | 75 | 1033208 | 100 | 1399575 |
| 6 | 93.75 | 1295106 | 125 | 1764674 |
| 7 | 112.5 | 1533037 | 150 | 2061337 |




Fig 9: Calibration curve of Escitalopram




Fig 10: Calibration curve of L-methylfolate

Table 3: Table of Accuracy

| Sample | Concentration (%) ($\mu\text{g/ml}$) | Recovery (%) | % RSD |
|----------------|---|--------------|-------|
| Escitalopram | 37.5 | 100.26 | 1.50 |
| | 75 | 99.72 | 0.33 |
| | 112.5 | 98.48 | 0.18 |
| L-methylfolate | 50 | 100.04 | 1.00 |
| | 100 | 99.46 | 1.58 |
| | 150 | 100.46 | 0.72 |

Limit Of Detection

Limit of detection was calculated by std deviation method Escitalopram and L-methylfolate and LOD for Escitalopram and L-methylfolate were found to be 0.29 and 0.38 respectively.




Fig 11: LOD Chromatogram of Escitalopram and L-methylfolate

Table 4: Limit of Detection

| Peak Name | RT | Area | s/n | USP Plate count | USP Tailing |
|---------------|-------|-------|-------|-----------------|-------------|
| Escitalopram | 3.063 | 43578 | 240.8 | 10142.1 | 0.7 |
| L-methylfolat | 3.676 | 63952 | 364.7 | 10719.7 | 1.1 |

Limit of Quantitation

Limit of Quantification was calculated by std deviation method Escitalopram and L-methylfolate and LOQ for Escitalopram and L-methylfolate were found to be 0.89 and 1.15 respectively.




Fig 12: LOQ Chromatogram of of Escitalopram and L-methylfolate

Table 5: limit of quantitation

| Peak Name | RT | Area | s/n | USP Plate count | USP Tailing |
|---------------|-------|-------|-------|-----------------|-------------|
| Escitalopram | 3.064 | 27027 | 124.7 | 9278.6 | 0.7 |
| L-methylfolat | 3.676 | 39883 | 211.0 | 10989.4 | 1.1 |

Table 6: Robustness data of Escitalopram and L-methylfolate

| S.NO | Robustness condition | Escitalopram %RSD | L-methylfolate %RSD |
|------|--------------------------------------|----------------------|------------------------|
| 1 | Flow minus(0.9ml/min) | 0.1 | 0.1 |
| 2 | Flow Plus(1.1ml/min) | 0.0 | 0.1 |
| 3 | Mobile phase minus(50:50) | 0.7 | 0.7 |
| 4 | Mobile phase Plus(45:55) | 0.1 | 0.1 |
| 5 | Temperature minus(25 ^{0c}) | 0.1 | 0.1 |
| 6 | Temperature Plus(30 ^{0c}) | 0.1 | 0.1 |

DISCUSSION

As per above observations, it was found that the % Relative standard deviation of replicate injections of standard preparations with ± 0.1 flow rate and ± 5 nm wavelength was found to be 2.0%. Also system suitability parameters such as Tailing, Tangent / Column efficiency and %RSD of replicate injections of standard preparation, are meeting the requirements. Hence the proposed method is

robust for the estimation of Enalapril and Felodipine even with variation of different flow rate.

Assay: Standard preparations are made from the API and Sample Preparations are from Formulation. Both sample and standards are injected six homogeneous samples. Drug in the formulation was estimated by taking the standard as the reference. The Average %Assay was calculated and found to be 100.5% and 100.37% for Escitalopram and L-methylfolate respectively




Fig 13: Assay of Tablet

Table 7: Assay of Tablet

| S. No. | Escitalopram %Assay | L-methylfolate %Assay |
|--------|---------------------|-----------------------|
| 1 | 99.63 | 99.60 |
| 2 | 99.59 | 99.40 |
| 3 | 101.42 | 101.09 |
| 4 | 100.36 | 101.36 |
| 5 | 101.80 | 101.11 |
| 6 | 100.23 | 99.66 |
| AVG | 100.5 | 100.37 |
| STDEV | 0.9171 | 0.9049 |
| %RSD | 0.91 | 0.90 |

Degradation studies

Standards and degraded samples are injected and calculated the percentage of drug degraded in solution by applying different conditions like acid, alkali, oxidative, photolytic, thermal and neutral analysis.

Table 8: Degradation data

| Type of degradation | Escitalopram | | | L-methylfolate | | |
|---------------------|--------------|------------|------------|----------------|------------|------------|
| | AREA | %RECOVERED | % DEGRADED | AREA | %RECOVERED | % DEGRADED |
| Acid | 1002308 | 96.99 | 3.01 | 1338711 | 95.44 | 4.56 |
| Base | 1004372 | 97.19 | 2.81 | 1363642 | 97.22 | 2.78 |
| Peroxide | 1013347 | 98.06 | 1.94 | 1380153 | 98.39 | 1.61 |
| Thermal | 1028055 | 99.49 | 0.51 | 1390184 | 99.11 | 0.89 |
| Uv | 1031605 | 99.83 | 0.17 | 1398277 | 99.68 | 0.32 |
| Water | 1030472 | 99.72 | 0.28 | 1396733 | 99.57 | 0.43 |

SUMMARY AND CONCLUSION

Table 9: Summary of Validation Parameters

| S.No. | Validation Parameters | Requirement | Results | | Acceptance Criteria |
|-------|-----------------------|-------------------------|--------------|----------------|---------------------|
| | | | Escitalopram | L-methylfolate | |
| 1. | Specificity | No Interference | Pass | Pass | No Interference |
| 2. | Linearity | Correlation Coefficient | 0.999 | 0.999 | NLT 0.999 |
| 3. | Accuracy | %Recovery | 99.48% | 99.98% | 100 ± 2% |
| 4. | Method Precision | %RSD | 0.5 | 1 | NMT 2% |
| | Ruggedness | | 0.9 | 0.9 | NMT 1% |
| 5. | Robustness | %RSD | 0.97 | 0.57 | NMT 1% |
| 6 | LOD | | 0.29 µg/ml | 0.38 µg/ml | |
| 7 | LOQ | | 0.89 µg/ml | 1.15 µg/ml | |
| 8. | System Suitability | RT | 3.046 min | 3.662 min | - |
| | | Tailing Factor | 1.07 | 1.19 | NMT 2 |
| | | Plate Count | 8669 | 10198 | NLT 4000 |
| | | Assay Value | 100.5% | 100.37% | 100 ± 2% |

CONCLUSION

A novel, sensitive, accurate, specific, precise method was developed for the Simultaneous estimation of Escitalopram and L-methylfolate in tablet dosage form by

RP-HPLC Method. The method was validated as for ICH guidelines and it can be used for the routine analysis of Escitalopram and L-methylfolate in tablet dosage form.

REFERENCES

1. R. S. Satoskar, S.D. Bhandarkar and S. S. Ainapure. "Pharmacology and Pharmacotherapeutics", 17th edition, Popular Prakashan, Mumbai, India, 2001.

2. "Burger's Medicinal Chemistry and drug discovery", 6 th edition, Wiley Interscience, New Jersey, 2007.
3. "Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry", 11th edition, Lippincott Williams & Wilkins, New york, 2004.
4. Korolkovas. "Essentials of Medicinal Chemistry", 2nd edition, Wiley Interscience, New Jersey, 1988.
5. "Goodman and Gilman's The Pharmacological Basis of Therapeutics", 9th edition, McGraw-Hill health professions division, New york, 1996.
6. Foye's "Principles of Medicinal Chemistry", 6th edition, Lippincott Williams & Wilkins, New york, 2008.
7. Drugs & Cosmetics Act, 1940 & Rules, 1945, 2nd edition, Susmit publishers, Mumbai, India, 2000.
8. Indian Pharmacopoeia, Ministry of Health & Family Welfare, Government of India, New Delhi, 1996.
9. The United States Pharmacopoeia- the National Formulary, United States Pharmacopoeial convention, Rockville, 2007.
10. British Pharmacopoeia, The Stationary Office, London, 2005.
11. "Martindale - The Extra Pharmacopoeia", 33rd edition, The Pharmaceutical Press, London, 2002. 7
12. H. Beckett and J. B. Stenlake. "Practical Pharmaceutical Chemistry", Volume I and II, CBS Publishers & Distributors, New Delhi, India, 2000.
13. P. D. Sethi. "Quantitative Analysis of Drugs in Pharmaceutical Formulations". 3 rd edition, CBS Publishers & Distributors, New Delhi, India, 1997.
14. H. H. Willard, L. L. Merrit, J. A. Dean and F. A. Settle. "Instrumental Method of Analysis", 7th edition, CBS Publishers & Distributors, New Delhi, India, 1986.
15. R. A. Day and A. L. Underwood. "Quantitative Analysis", 6th edition, PHI learning private limited, New Delhi, India, 2009.
16. G. Ramana Rao, S. S. N. Murthy and P. Khadgpathi. Gas chromatography to pharmaceutical analysis (Review). Eastern Pharmacist. 30(353): 35 (1987).
17. G. Ramana Rao, S. S. N. Murthy and P. Khadgpathi. High performance liquid chromatography and its role in pharmaceutical analysis (Review). Eastern Pharmacist. 29 (346): 53 (1986).
18. Li-Yord R. Snyder, Joseph J. Kirkland and Joseph L. Glajch. Practical HPLC Method development. John Wiley & Sons, INC, U.S.A. 2 nd Edition, New York, 1997.
19. Satinder Ahuja and Michael W. Dong. Handbook of Pharmaceutical Analysis by HPLC, Elsevier academic press, 1 st Edition, Vol. 6, 2005.
20. M. Thompson, S. L. R. Ellison and R. Wood. Harmonized guidelines for single laboratory validation of methods of analysis. Pure Appl. Chem. 74(5): 835- 855(2002)8